Navigation Links
Fibrillation in Medical Technology

FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)

... (FDA) to treat patients with non-permanent atrial fibrillation (AF). As demonstrated in the ATHENA trial, ... reviewing new drug applications. Atrial fibrillation is the leading cause of hospitalization for ... fold) in recent years in the U.S. Atrial fibrillation is a complex disease that increases the risk of ...

New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation

... or death by 24 percent in patients with atrial fibrillation - PARIS, Feb. 11 /PRNewswire-FirstCall/ -- ... vs. 39.4%, p<0.001) in patients with atrial fibrillation (AF)/atrial flutter (AFL) or a recent history of these conditions. Atrial fibrillation is the leading cause of hospitalization for ...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

... -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose ... evaluating an oral Factor Xa inhibitor in atrial fibrillation patients. DU-176b is being developed solely by ... A total of 1,146 patients with atrial fibrillation with a CHADS2 index >/= 2 were enrolled in the ...

Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation

... with Factor Xa Next Generation in Atrial fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with ... of clotting or stroke in patients with atrial fibrillation other than the current standard of care, ... cardiovascular portfolio." About Atrial fibrillation ...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

... of hospital days by 28% in patients with atrial fibrillation or flutter NEW ORLEANS, Nov. 11 ... Fewer patients developed permanent atrial fibrillation during the study in the dronedarone group - 178 ... groups. About Atrial Fibrillation Atrial fibrillation (AF) is a common heart arrhythmia in which ...

Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

... the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately ... 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by ... to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic ...

Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

... the Risk of Stroke by 34% in Patients With Atrial fibrillation or Atrial Flutter Already Adequately Treated by ... 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by ... to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic ...

Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies

... paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation (PAF) is characterized by a rapid rhythm of the ... drug therapy and were free of atrial fibrillation 9 months (+/- 2 months) following a single ... so many patients with paroxysmal atrial fibrillation are visiting their healthcare provider for ...

Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation

... in patients with Atrial Fibrillation." Atrial fibrillation is a major cause of hospitalization and ... congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly ... prevention and treatment of patients with atrial fibrillation or atrial flutter. Dronedarone is a ...

Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times

... positive findings about its novel atrial fibrillation catheter ablation system were presented at ... considerably shortened procedure times." Atrial fibrillation (AF) is a common and devastating cardiac ... to helping individuals suffering from atrial fibrillation and other cardiac arrhythmias. Working in concert ...

Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients

... the advanced ablation system to treat atrial fibrillation (AF) patients in commercial procedures throughout ... the Center for the Advanced Management of Atrial fibrillation at the Brigham and Women's Hospital in Boston. ... and permanent AF populations." Atrial fibrillation is a common and devastating cardiac rhythm ...

ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... conference entitled, "New Perspectives in Atrial fibrillation Management" chaired by John Camm, Professor of ... ERATO, and the ongoing DIONYSOS trial. Atrial fibrillation is a major cause of hospitalization and ... congestive heart failure. About Atrial fibrillation / Flutter ...

ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... conference entitled "New Perspectives in Atrial fibrillation Management" chaired by John Camm, Professor of ... between the 2 study groups. Atrial fibrillation is a major cause of hospitalisation and ... and the ongoing DIONYSOS trial. About Atrial fibrillation / Flutter ...

Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation

... therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of ... and antithrombotic drugs, in patients with atrial fibrillation or atrial flutter. Multaq(R) also significantly ... of atrial fibrillation management. For atrial fibrillation patients, who together with their physicians ...

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

... is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in ... INR 2.0-3.0) in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke. ... our original expectations by far." Atrial fibrillation is the most common sustained cardiac ...

FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial

... of Chronic Atrial fibrillation Patients CARLSBAD, Calif., Jan. 16 /PRNewswire/ ... for interventional treatment of chronic atrial fibrillation (AF). Approval from the US Food and Drug ... in the US. About Atrial Fibrillation Atrial fibrillation remains the most commonly diagnosed ...

ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia

... effect in preventing atrial fibrillation and life threatening ventricular arrhythmia, ... New Data on Bucindolol in Atrial fibrillation and Ventricular Arrhythmia Data from the Phase 3 ... clinically important arrhythmic conditions-atrial fibrillation (AF) and life threatening ventricular arrhythmias ...

Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset

... (sinus rhythm, or SR) in patients with atrial fibrillation (AF) treated within 48 hours of the onset of ... vs. 1.7 percent, respectively). About Atrial fibrillation Atrial fibrillation (AF) is an interruption of the normal sinus ...

CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation

... our lead over other companies conducting atrial fibrillation ablation pivotal trials and brings us one step ... of approval for the treatment of atrial fibrillation in 2009." Helen Barold, M.D. Chief Medical ... lead time over other companies conducting atrial fibrillation ablation pivotal trials, ability of obtain FDA ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events ... study, Effective Anticoagulation with Factor Xa Next Generation in Atrial fibrillation (ENGAGE-AF), is comparing edoxaban with warfarin (INR2-3) for the ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

... the procedure reduces the chance that patients will experience atrial fibrillation over the long term. The report, which compared radiofrequency ... at risk for heart failure, blood clots, or stroke. Patients with atria fibrillation are typically treated with medication first, but medicines only work for ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... conditions can elevate a person's risk of clotting, including atrial fibrillation (an abnormal heart rhythm), previous heart attack, long periods of ... dose of warfarin is given. A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of ...

Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke

... - Large, International REACH Registry Also Shows Many Patients With Atrial fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their risk for cardiovascular death, heart attack ...

American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation

... persistent (responsive to cardioversion) or permanent (continuous atrial fibrillation with cardioversion proven or deemed ineffective). In patients with ... decreased ventricular rate during a first recurrence of atrial fibrillation in paroxysmal and persistent AF patients. The well- proven ...

HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China

... Phase I studies completed in China, HBI-3000 was well tolerated. Atrial fibrillation (AF) is a serious type of arrhythmia found in approximately 2.2 million ... being developed and investigated for use as IV treatment of atrial fibrillation with clinical trials expected to begin in early 2009. "This is a ...

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm

... that 75 of the 145 (51.7%) KYNAPID patients in the short-duration atrial fibrillation (AF) group (3 hours to 7 days) converted to sinus rhythm within 90 minutes ... for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our ...

ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line

... technique developed by Dr. James L. Cox in the 1980s to treat atrial fibrillation (AF) with a high rate of long-term success. (Logo: ... the ATS CryoMaze products the source for the surgical treatment of atrial fibrillation through less-invasive approaches. The team's focus is on developing tools ...

Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation

... tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR). The Committee voted against approval of ... FDA on or before January 19, 2008. About Atrial Fibrillation Atrial fibrillation (AFib) is an abnormal heart rhythm, known as a cardiac arrhythmia, ...

Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery

... to normal heart rhythm (sinus rhythm, or SR) in patients with atrial fibrillation (AF) following coronary artery bypass graft (CABG) or valvular surgeries. ... were no deaths or cases of torsade de pointes. About Atrial fibrillation AF is an interruption of the normal sinus rhythm (arrhythmia) of ...

CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway

... patients with symptomatic paroxysmal atrial fibrillation". About Atrial fibrillation AF is a potentially serious cardiac arrhythmia typically ... Society, The Task Force on Catheter and Surgical Ablation of Atrial fibrillation wrote: "There is a consensus among the Task Force that the primary ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

deCODE Receives California Clinical Laboratory License

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting

... LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke due to ...

deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

Major deCODE-led Study Underscores Role of the Brain in Obesity

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE ...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE ...

deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is ...

deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is ...
Other Contents
(Date:8/18/2014)... satellite image of Antarctica, and the imagery will help ... the effects of climate change. , Thanks to a ... and Associates Ltd. (MDA), the prime contractor for the ... at UWaterloo, the mosaic is free and fully accessible ... Using Synthetic Aperture Radar with multiple polarization modes aboard ...
(Date:8/18/2014)... Researchers at UT Southwestern Medical Center have found a ... type of molecule known as long non-coding RNA. , The ... of many bodily functions, from waking and sleeping to body ... cycle that is influenced by external cues such as light ... are abundant in many organisms, what they do in the ...
(Date:8/18/2014)... small body size associated with the pygmy phenotype ... according to an international team of researchers, but ... same genetic underpinning, suggesting a more recent adaptation ... hunter-gatherers have adapted to their very challenging environments," ... and biology, Penn State. "Tropical rainforests are difficult ...
Breaking Biology News(10 mins):Waterloo makes public most complete Antarctic map for climate research 2Researchers obtain key insights into how the internal body clock is tuned 2Researchers obtain key insights into how the internal body clock is tuned 3Pygmy phenotype developed many times, adaptive to rainforest 2
(Date:8/19/2014)... (PRWEB) August 20, 2014 The elegant ... people can upgrade their houses in an environmentally conscious ... made of solid materials and have an aluminum oxide ... them well suited for high-traffic areas. , Recently, the ... strand woven bamboo floorings . These fresh items are ...
(Date:8/19/2014)... 20, 2014 Midtown Dentistry in Houston, Texas, ... office. All patients with cavities, or with old fillings ... fillings that can safely repair and restore teeth. , From ... latest materials, all of which are completely amalgam free. Even ... use by the FDA for adults and children over the ...
(Date:8/19/2014)... 2014 What gives skin an edge and ... skin, replenish and nourish it while lightly exfoliating? The ... after client raves about how their skin feels and looks ... Sublime Beauty®. "The ingredients are very rich and spa-quality." ... smooth it over cleansed skin of the face and neck, ...
(Date:8/19/2014)... in this week,s JAMA highlights the importance ... considering how to treat patients. Written by Robert Vinci, ... chair of pediatrics at Boston University School of Medicine ... the editorial examines results of a study published in ... of how doctors can often over-emphasize certain types of ...
(Date:8/19/2014)... a popular supplier of fashionable wedding, bridesmaid, evening, prom, ... a discount of up to 67% on all ... outfits are available in different necklines; ladies can choose ... are over 400 cheap white prom dresses listed in ... valid until August 29, 2014. The discounted products feature ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com Announces Up To 30% Discount On Its New Click Strand Woven Bamboo Floorings 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:That "Something Special" to Improve Skin Takes Only 10 Minutes Per Week; on Sale at Sublime Beauty® 2Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2
Other TagsOther Tags